Please enter verification code
Confirm
Association between Tumor Stage and Grade and Mean Platelet Volume in Patients with Renal Cell Carcinoma
Clinical Medicine Research
Volume 3, Issue 2, March 2014, Pages: 36-39
Received: Mar. 3, 2014; Published: Mar. 30, 2014
Views 3313      Downloads 243
Authors
Ibrahim Keles, Department of urology, Kocatepe University, Medical Faculty, Afyon, Turkey
Cavit Ceylan, Department of urology, Turkey Yuksek Ihtisas Education and Research Hospital, Ankara, Turkey
Erdogan Aglamis, Department of urology, Elazig Education and Research Hospital, Elazig, Turkey
Hasan Salih Saglam, Department of urology, Sakarya University, Medical Faculty, Sakarya, Turkey
Mustafa Karalar, Department of urology, Kocatepe University, Medical Faculty, Afyon, Turkey
Soner Coban, Department of urology, Sevket Yilmaz Education and Research Hospital, Bursa, Turkey
Sait Bicer, Department of urology, Turkey Yuksek Ihtisas Education and Research Hospital, Ankara, Turkey
Oztug Adsan, Department of urology, Sakarya University, Medical Faculty, Sakarya, Turkey
Mehmet Ozgur Yucel, Department of urology, Adiyaman University, Education and Research Hospital, Adiyaman, Turkey
Article Tools
PDF
Follow on us
Abstract
Purpose: To research association between Mean Platelet Volume (MPV) and tumor stage and grade in non-metastatic renal cell carcinomas in circumstances of hypoxia, thromboembolism, and ischemia, based on MPV increase. Material and methods: Data of 104 non-metastatic patients, in whom nephrectomy was done and whose pathology resulted in renal cell carcinoma, have been evaluated retrospectively. The patients were clinically classified as T1a, T1b, T2a, T2b according to TNM stage and as Fuhrman Grade 1, 2, 3, 4 according to pathology results. Preoperative mean platelet number and MPV values of the patients were compared with their tumor stage and grade. Results: Sixteen (15%) were in T1a, 41 (39%) were in T1b, 39 (38%) were in T2a, and 8 (7%) of the patients were in T2b clinical stage. According to pathology results, 21 (20%) were assessed as Fuhrman grade I, 59 (57%) were grade II, 22 (21%) were grade III, and 2 (2%) of the patients were grade IV. Mean MPV values were 8.50±1.39, 8.51±1.25, 8.65±1.12, and 8.95±0.07 in Grade I, II, III, IV, respectively. A positive correlation was present between mean MPV and grade (r= 0.052, p=0.599). As long as grade increases, mean MPV values were observed to increase. However, no statistically difference was determined between tumor grade and mean MPV and platelet (p values: 0.935 and 0.963, respectively). No statistically significant difference was detected between tumor stage and mean MPV and platelet (p values: 0.996 and 0.397, respectively). Conclusion: A positive correlation was observed to be between mean MPV values and tumor grade. However, no statistically significant difference was determined. It can be supported with the larger series that MPV for renal tumors, that is rapidly and expansively growing tumor, can be an effective biochemical indicator in early diagnosis, staging, and evaluation of response to treatment.
Keywords
Renal Cell Carcinoma, Stage, Grade, Mean Platelet Volume
To cite this article
Ibrahim Keles, Cavit Ceylan, Erdogan Aglamis, Hasan Salih Saglam, Mustafa Karalar, Soner Coban, Sait Bicer, Oztug Adsan, Mehmet Ozgur Yucel, Association between Tumor Stage and Grade and Mean Platelet Volume in Patients with Renal Cell Carcinoma, Clinical Medicine Research. Vol. 3, No. 2, 2014, pp. 36-39. doi: 10.11648/j.cmr.20140302.16
References
[1]
Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58:71–96.
[2]
Erdemir F, Parlaktas BS, Uluocak N, Ozcan F, Celik M, Gokce O. The significance of serum ferritin level in renal cell carcinima. Turk J Urol 2005; 31 (4): 479-484.
[3]
Gogus C, Baltaci S, Filiz E, Elhan A, Beduk Y: Significance of thrombocytosis for determining prognosis in patients with localized renal cell carcinoma. Urology 2004; 63: 447- 450.
[4]
Van Poppel H. Conservative vs radical surgery for renal cell carcinoma. BJU Int 2004; 94: 766-768.
[5]
Ali MA, Akhmedkhanov A, Zeleniuch-Jaquotte A, Toniolo P, Frenkel K, Huang X. Reliability of serum iron, ferritin, nitrite, and association with risk of renal cancer in women. Cancer Detect Prev 2003; 27: 116-121.
[6]
Miyata Y, Koga S, Nishikido M, Hayashi T, Kanetake H. Relationship between serum ferritin levels and tumor status in patients with renal cell carcinoma. BJU Int 2001; 88: 974-977.
[7]
Karaman K, Bostanci EB, Aksoy E, et al. The predictive value of mean platelet volume in differential diagnosis of non-functional pancreatic neuroendocrine tumors from pancreatic adenocarcinomas. Eur J Intern Med 2011; 22: 95–98.
[8]
Cil H, Yavuz C, İslamoglu Y, et al. Platelet Count and Mean Platelet Volume in Patients With In-Hospital Deep Venous Thrombosis. Clin Appl Thromb Hemost 2012; 18(6): 650-3.
[9]
Kamath S, Blann AD, Lip GY. Platelet activation: assessment and quantification. Eur Heart J 2001; 22:1561-1571.
[10]
Park Y, Schoene N, Haris W. Meanplateletvolume as an indicator ofplateletactivation: methodologicalissues. Platelets 2002; 13:301-306.
[11]
Tsiara S, Elisaf M, Jagroop IA, et al. Platelets as predictors ofvascular risk: is there a practicalindex of plateletactivity? Clin Appl Thromb Hemost 2003; 9:177-190.
[12]
Martin JF, Shaw T, Heggie J, et al. Measurement of the density of platelets and its relationship to volume. Brit J Haematol 1983; 54:337-352.
[13]
Bath PM, Butterworth RJ. Platelet size: Measurement, physiology and vascular disease. Blood Coagul Fibrin 1996: 7:157-161.
[14]
Butterworth R, Bath P. The relationship between mean platelet volume, stroke subtype and clinical outcome. Platelets 1998: 9: 359-364.
[15]
Varol E, Ozturk O, Gonca T, et al. Mean platelet volume is increased in patients with severe obstructive sleep apnea. Scand J Clin Lab Invest 2010;70: 497-502.
[16]
Cookson MS: Glenn’s Urologic Surgery. Fifth edition. Chapter 7, 61-77, 1998.
[17]
Gelb AB: Renal cell carcinoma: Current prognostic factors. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997; 80: 981-986.
[18]
Kokocinska D, Rajchel K, Nalewajka E, Zagalski K. The usefulness of serum levels of CEA, CA 50, and ferritin in the management of renal cell cancer. J Environ Pathol Tox Oncol 1996; 15: 279-281.
[19]
Citterio G, Bertuzzi A, Tresoldi M, et al. Prognostic factors for survival in metastatic renal cell carcinoma: Retrospective analysis from 109 consecutive patients. Eur Urol 1997; 31: 286- 291.
[20]
Dexeus FH, Logothetis CJ, Sella A, et al. Serum biomarkers in metastatic renal cell carcinoma. Urology 1991; 38: 6-10.
[21]
Kirkali Z, Guzelsoy M, Mungan MU, Kirkali G, Yorukoglu K. Serum ferritin as a clinical marker for renal cell carcinoma: Influence of tumor size and volume. Urol Int 1999; 62: 21-25.
[22]
Sagit M, Korkmaz F, Kavugudurmaz M, Somdas MA. Impact of Septoplasty on Mean Platelet Volume Levels in Patients With Marked Nasal Septal Deviation. J Craniofac Surg 2012; 23: 974-976.
[23]
Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD. Mean platelet volume: a link between thrombosis and ınflammation? Curr Pharm Design 2011;17: 47–58.
[24]
Khandekar MM, Khurana AS, Deshmukh SD, Kakrani AL, Katdare AD, Inamdar AK. Platelet volume indices in patients with coronary artery disease and acute myocardial infarction: an Indian scenario. J Clin Pathol 2006; 59: 146–149.
[25]
Mutlu H, Berk V, Karaca H, Erden A, Aslan T, Akca Z. Treatment Regimen With Bevacizumab Decreases Mean Platelet Volume in Patients With Metastatic Colon Cancer. Clin Appl Thromb Hemost 2012; Sep 1: 546-548.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186